Diffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in life-threatening hemorrhage in a variety of other settings in which conventional therapy is unsuccessful. Randomized controlled trials of rFVIIa in DAH are lacking. However, several case reports have described a complete or sustained control of DAH using rFVIIa after patients failed to respond to medical treatment. There are no case reports in the literature describing the use or the failure of rFVIIa in DAH associated with cryoglobulinemic vasculitis. We here report the failure of rFVIIa to control DAH in a patient with CD5+ B-cell non-Hodgkin's lymphoma and cryoglobulinemic vasculitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119916 | PMC |
| http://dx.doi.org/10.1155/2014/283086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course.
Rheumatology (Oxford)
December 2024
AP-HP, Université Paris Saclay, department of internal medicine and clinical immunology, Bicêtre Hospital, Le Kremlin Bicêtre, France.
Objective: To describe presentation, treatment and outcome of immune checkpoint inhibitor (ICI) associated-vasculitis in cancer patients in a multicentre study.
Methods: Thanks to the ImmunoCancer International Registry (ICIR), a multidisciplinary network focused on the research of the immune related adverse events related to cancer immunotherapies, patients presenting with a clinical and/or radiological suspicion of vasculitis, and histological evidence of vasculitis after being exposed to ICIs were retrospectively identified.
Results: Twenty eight cases were identified in the ICIR registry.
Non-infectious mixed cryoglobulinemia as a new clinical presentation of mutation in the gene encoding coatomer subunit alpha: a case report of two adult sisters.
Front Immunol
December 2024
Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, Warsaw, Poland.
Cryoglobulinemia is a rare disease characterized by the presence of cryoglobulins in the blood serum. It is usually caused by autoimmune, lymphoproliferative, or infectious factors. The pathogenesis of cryoglobulinemia is not well understood, therefore, genetic testing is very important.
View Article and Find Full Text PDFA Rare Presentation of Cryoglobulinemic Vasculitis Associated with Primary Sjögren's Syndrome.
Curr Rheumatol Rev
September 2024
Department of Rheumatology, University of Southern California, 2011 Zonal Ave, Los Angeles, CA90033, United States.
Article Synopsis
- - Sjögren's syndrome is a chronic autoimmune disorder often causing dry eyes and mouth, and in rare cases, can lead to cryoglobulinemia, which results in serious systemic inflammation.
- - A case study of a 52-year-old woman with Sjögren's syndrome revealed she developed cryoglobulinemic vasculitis, causing severe complications like lower extremity weakness and renal issues.
- - Treatment with rituximab and steroids improved her condition, emphasizing the need for doctors to consider cryoglobulinemic vasculitis as a potential cause of multi-organ issues in patients with autoimmune diseases.
The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjögren's disease: a monocentric cohort study.
Clin Exp Rheumatol
December 2024
Rheumatology Division, Department of Medicine (DMED), University of Udine, and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
Objectives: To compare two different rituximab (RTX)-based therapeutic approaches on vasculitic and lymphoproliferative-related disease activity and on non-Hodgkin lymphoma (NHL) development in a cohort of patients affected by cryoglobulinaemic vasculitis secondary to Sjögren's disease (Sjögren-CryoVasc).
Methods: Three Sjögren-CryoVasc treatment groups were identified: 1) early RTX induction followed by maintenance; 2) late RTX induction with possible on-demand retreatment; 3) no RTX treatment. The following outcomes were evaluated: a) changes in cumulative ESSDAI, considering vasculitic-related and lymphoproliferative-related domains and changes in ESSDAI specific to each single vasculitic-related and lymphoproliferative-related domain; b) development of NHL; c) occurrence of persistent hypogammaglobulinemia associated with serious infections.
Recurrent localized fever caused by cryoglobulinemic vasculitis following hemodialysis: A case report.
CEN Case Rep
August 2024
Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
Article Synopsis
- Post-dialysis fever is a frequent issue for patients on hemodialysis, but pinpointing its cause can be difficult due to various factors.
- A 66-year-old man experienced persistent fevers that were initially attributed to pneumonia, only to later reveal that it was actually caused by alveolar hemorrhage from cryoglobulinemic vasculitis.
- Treatment involving plasma exchange and managing dialysate temperature effectively reduced the fevers, highlighting the need to consider cryoglobulinemia in similar cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!